Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Richmond JM, Strassner JP, Zapata L Jr, Garg M, Riding RL, Refat MA, Fan X, Azzolino V, Tovar-Garza A, Tsurushita N, Pandya AG, Tso JY, Harris JE.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaam7710. doi: 10.1126/scitranslmed.aam7710.

2.

CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms.

Yuan X, Dong Y, Tsurushita N, Tso JY, Fu W.

JCI Insight. 2018 Jan 25;3(2). pii: 96600. doi: 10.1172/jci.insight.96600. eCollection 2018 Jan 25.

3.

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB.

Clin Cancer Res. 2008 May 1;14(9):2775-84. doi: 10.1158/1078-0432.CCR-07-4246.

4.

Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies.

Akamatsu Y, Pakabunto K, Xu Z, Zhang Y, Tsurushita N.

J Immunol Methods. 2007 Oct 31;327(1-2):40-52. Epub 2007 Aug 2.

PMID:
17719061
5.

Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies.

Hartman TE, Sar N, Genereux K, Barritt DS, He Y, Burky JE, Wesson MC, Tso JY, Tsurushita N, Zhou W, Sauer PW.

Biotechnol Bioeng. 2007 Feb 1;96(2):294-306.

PMID:
16897745
6.

An engineered human IgG1 antibody with longer serum half-life.

Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N.

J Immunol. 2006 Jan 1;176(1):346-56.

7.

Design of humanized antibodies: from anti-Tac to Zenapax.

Tsurushita N, Hinton PR, Kumar S.

Methods. 2005 May;36(1):69-83.

PMID:
15848076
8.

Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice.

Bhagavathula N, Nerusu KC, Fisher GJ, Liu G, Thakur AB, Gemmell L, Kumar S, Xu ZH, Hinton P, Tsurushita N, Landolfi NF, Voorhees JJ, Varani J.

Am J Pathol. 2005 Apr;166(4):1009-16.

9.

Humanization of a chicken anti-IL-12 monoclonal antibody.

Tsurushita N, Park M, Pakabunto K, Ong K, Avdalovic A, Fu H, Jia A, Vásquez M, Kumar S.

J Immunol Methods. 2004 Dec;295(1-2):9-19.

PMID:
15627607
10.

Characterization of humanized antibodies secreted by Aspergillus niger.

Ward M, Lin C, Victoria DC, Fox BP, Fox JA, Wong DL, Meerman HJ, Pucci JP, Fong RB, Heng MH, Tsurushita N, Gieswein C, Park M, Wang H.

Appl Environ Microbiol. 2004 May;70(5):2567-76.

11.

Engineered human IgG antibodies with longer serum half-lives in primates.

Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vásquez M, Tsurushita N.

J Biol Chem. 2004 Feb 20;279(8):6213-6. Epub 2003 Dec 29.

12.

The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody.

Landolfi NF, Thakur AB, Fu H, Vásquez M, Queen C, Tsurushita N.

J Immunol. 2001 Feb 1;166(3):1748-54.

13.

IFN-gamma inhibits activation-induced expression of E- and P-selectin on endothelial cells.

Melrose J, Tsurushita N, Liu G, Berg EL.

J Immunol. 1998 Sep 1;161(5):2457-64.

14.
15.

Epitope mapping of mouse monoclonal antibody EP-5C7 which neutralizes both human E- and P-selectin.

Tsurushita N, Fu H, Melrose J, Berg EL.

Biochem Biophys Res Commun. 1998 Jan 6;242(1):197-201.

PMID:
9439635
16.
17.

PCR cloning of the cDNA encoding baboon L-selectin.

Tsurushita N, Fu H, Berg EL.

Gene. 1996 Nov 28;181(1-2):219-20.

PMID:
8973334
18.

Isolation and characterization of neutralizing single-chain antibodies against Xenopus mitogen-activated protein kinase kinase from phage display libraries.

Kosako H, Akamatsu Y, Tsurushita N, Lee KK, Gotoh Y, Nishida E.

Biochemistry. 1996 Oct 8;35(40):13212-21.

PMID:
8855960
19.

E-selectin appears in nonischemic tissue during experimental focal cerebral ischemia.

Haring HP, Berg EL, Tsurushita N, Tagaya M, del Zoppo GJ.

Stroke. 1996 Aug;27(8):1386-91; discussion 1391-2.

PMID:
8711807
21.

Antibodies cross-reactive with E- and P-selectin block both E- and P-selectin functions.

Berg EL, Fromm C, Melrose J, Tsurushita N.

Blood. 1995 Jan 1;85(1):31-7.

22.

Essential residues in V(D)J recombination signals.

Akamatsu Y, Tsurushita N, Nagawa F, Matsuoka M, Okazaki K, Imai M, Sakano H.

J Immunol. 1994 Nov 15;153(10):4520-9.

PMID:
7963524
23.

Construction of a human Ig combinatorial library from genomic V segments and synthetic CDR3 fragments.

Akamatsu Y, Cole MS, Tso JY, Tsurushita N.

J Immunol. 1993 Nov 1;151(9):4651-9.

PMID:
8409426
25.

Nuclear factors in B lymphoma enhance splicing of mouse membrane-bound mu mRNA in Xenopus oocytes.

Tsurushita N, Ho L, Korn LJ.

Science. 1988 Jan 29;239(4839):494-7.

PMID:
3124268
26.

Site-directed mutagenesis with Escherichia coli DNA polymerase III holoenzyme.

Tsurushita N, Maki H, Korn LJ.

Gene. 1988;62(1):135-9.

PMID:
3286374
27.
28.

Regulation of differential processing of mouse immunoglobulin mu heavy-chain mRNA.

Tsurushita N, Avdalovic NM, Korn LJ.

Nucleic Acids Res. 1987 Jun 11;15(11):4603-15.

29.

Overproduction of transcription termination factor Rho in Escherichia coli.

Shigesada K, Tsurushita N, Matsumoto Y, Imai M.

Gene. 1984 Jul-Aug;29(1-2):199-209.

PMID:
6092221
30.

Isolation and characterization of rho mutants of Escherichia coli with increased transcription termination activities.

Tsurushita N, Hirano M, Shigesada K, Imai M.

Mol Gen Genet. 1984;196(3):458-64.

PMID:
6094973

Supplemental Content

Loading ...
Support Center